|
1
|
Alvaro D, Crocetti E, Ferretti S, Bragazzi
MC and Capocaccia R; AISF Cholangiocarcinoma committee, :
committee, Descriptive epidemiology of cholangiocarcinoma in Italy.
Dig Liver Dis. 42:490–495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khan SA, Davidson BR, Goldin R, Pereira
SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Homas HC,
Thursz MR and Wasan H; British Society of Gastroenterology, :
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
Consensus document. Gut. 51 Suppl 6:VI1–VI9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taylor-Robinson SD, Toledano MB, Arora S,
Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P and Thomas HC:
Increase in mortality rates from intrahepatic cholangiocarcinoma in
England and Wales 1968–1998. Gut. 48:816–820. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khan SA, Taylor-Robinson SD, Toledano MB,
Beck A, Elliott P and Thomas HC: Changing international trends in
mortality rates for liver, biliary and pancreatic tumours. J
Hepatol. 37:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gores GJ: Cholangiocarcinoma: Current
concepts and insights. Hepatology. 37:961–969. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Casavilla FA, Marsh JW, Iwatsuki S, Todo
S, Lee RG, Madariaga JR, Pinna A, Dvorchik I, Fung JJ and Starzl
TE: Hepatic resection and transplantation for peripheral
cholangiocarcinoma. J Am Coll Surg. 185:429–436. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohtsuka M, Ito H, Kimura F, Shimizu H,
Togawa A, Yoshidome H and Miyazaki M: Results of surgical treatment
for intrahepatic cholangiocarcinoma and clinicopathological factors
influencing survival. Br J Surg. 89:1525–1531. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Isaji S, Kawarada Y, Taoka H, Tabata M,
Suzuki H and Yokoi H: Clinicopathological features and outcome of
hepatic resection for intrahepatic cholangiocarcinoma in Japan. J
Hepatobiliary Pancreat Surg. 6:108–116. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Li J, Xia Y, Gong R, Wang K, Yan
Z, Wan X, Liu G, Wu D, Shi L, et al: Prognostic nomogram for
intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin
Oncol. 31:1188–1195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fong Y, Jarnagin W and Blumgart LH:
Gallbladder cancer: Comparison of patients presenting initially for
definitive operation with those presenting after prior noncurative
intervention. Ann Surg. 232:557–569. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burke EC, Jarnagin WR, Hochwald SN,
Pisters PW, Fong Y and Blumgart LH: Hilar Cholangiocarcinoma:
Patterns of spread, the importance of hepatic resection for
curative operation, and a presurgical clinical staging system. Ann
Surg. 228:385–394. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xie D, Ren Z, Fan J and Gao Q: Genetic
profiling of intrahepatic cholangiocarcinoma and its clinical
implication in targeted therapy. Am J Cancer Res. 6:577–586.
2016.PubMed/NCBI
|
|
15
|
Brandi G, Farioli A, Astolfi A, Biasco G
and Tavolari S: Genetic heterogeneity in cholangiocarcinoma: A
major challenge for targeted therapies. Oncotarget. 6:14744–14753.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sia D, Tovar V, Moeini A and Llovet JM:
Intrahepatic cholangiocarcinoma: Pathogenesis and rationale for
molecular therapies. Oncogene. 32:4861–4870. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang K, Karnad A, Zhao S and Freeman JW:
Roles of c-Met and RON kinases in tumor progression and their
potential as therapeutic targets. Oncotarget. 6:3507–3518. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mueller KL, Madden JM, Zoratti GL,
Kuperwasser C, List K and Boerner JL: Fibroblast-secreted
hepatocyte growth factor mediates epidermal growth factor receptor
tyrosine kinase inhibitor resistance in triplenegative breast
cancers through paracrine activation of Met. Breast Cancer Res.
14:R1042012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeh CN, Maitra A, Lee KF, Jan YY and Chen
MF: Thioacetamide-induced intestinal-type cholangiocarcinoma in
rat: An animal model recapitulating the multi-stage progression of
human cholangiocarcinoma. Carcinogenesis. 25:631–636. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yeh CN, Lin KJ, Hsiao IT, Yen TC, Chen TW,
Jan YY, Chung YH, Lin CF and Chen MF: Animal PET for
thioacetamide-induced rat cholangiocarcinoma: A novel and reliable
platform. Mol Imaging Biol. 10:209–216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Young H, Baum R, Cremerius U, Herholz K,
Hoekstra O, Lammertsma AA, Pruim J and Price P: Measurement of
clinical and subclinical tumour response using
[18F]-fluorodeoxyglucose and positron emission
tomography: Review and 1999 EORTC recommendations. European
Organization for Research and Treatment of Cancer (EORTC) PET Study
Group. Eur J Cancer. 35:1773–1782. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Follenzi A, Bakovic S, Gual P, Stella MC,
Longati P and Comoglio PM: Cross-talk between the proto-oncogenes
Met and Ron. Oncogene. 19:3041–3049. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paik KY, Jung JC, Heo JS, Choi SH, Choi DW
and Kim YI: What prognostic factors are important for resected
intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol.
23:766–770. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nanashima A, Sumida Y, Abo T, Nagasaki T,
Takeshita H, Fukuoka H, Sawai T, Tanaka K, Yasutake T and Nagayasu
T: Patient outcome and prognostic factors in intrahepatic
cholangiocarcinoma after hepatectomy. Hepatogastroenterology.
54:2337–2342. 2007.PubMed/NCBI
|
|
25
|
Sano T, Shimada K, Sakamoto Y, Ojima H,
Esaki M and Kosuge T: Prognosis of perihilar cholangiocarcinoma:
Hilar bile duct cancer versus intrahepatic cholangiocarcinoma
involving the hepatic hilus. Ann Surg Oncol. 15:590–599. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yeh CN, Wang SY, Chen YY, Chen MH, Chiang
KC, Cheng CT, Tsai CY, Wang CC, Yeh TS and Chen TC: A prognostic
nomogram for overall survival of patients after hepatectomy for
intrahepatic cholangiocarcinoma. Anticancer Res. 36:4249–4258.
2016.PubMed/NCBI
|
|
27
|
Chen MF, Tsai HP, Jeng LB, Lee WC, Yeh CN,
Yu MC and Hung CM: Prognostic factors after resection for
hepatocellular carcinoma in noncirrhotic livers: Univariate and
multivariate analysis. World J Surg. 27:443–447. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yeh CN, Chen MF, Lee WC and Jeng LB:
Prognostic factors of hepatic resection for hepatocellular
carcinoma with cirrhosis: Univariate and multivariate analysis. J
Surg Oncol. 81:195–202. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeh CN, Lee WC and Chen MF: Hepatic
resection and prognosis for patients with hepatocellular carcinoma
larger than 10 cm: Two decades of experience at Chang Gung Memorial
Hospital. Ann Surg Oncol. 10:1070–1076. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Klompje J, Petrelli NJ, Herrera L and
Mittelman A: The prognostic value of preoperative alkaline
phosphatase for resection of solitary liver metastasis from
colorectal carcinoma. Eur J Surg Oncol. 13:345–347. 1987.PubMed/NCBI
|
|
31
|
Camp ER, Liu W, Fan F, Yang A, Somcio R
and Ellis LM: RON, a tyrosine kinase receptor involved in tumor
progression and metastasis. Ann Surg Oncol. 12:273–281. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leelawat K, Leelawat S, Tepaksorn P,
Rattanasinganchan P, Leungchaweng A, Tohtong R and Sobhon P:
Involvement of c-Met/hepatocyte growth factor pathway in
cholangiocarcinoma cell invasion and its therapeutic inhibition
with small interfering RNA specific for c-Met. J Surg Res.
136:78–84. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Herynk MH and Radinsky R: The coordinated
functional expression of epidermal growth factor receptor and c-Met
in colorectal carcinoma metastasis. In Vivo. 14:587–596.
2000.PubMed/NCBI
|
|
34
|
Comperat E, Roupret M, Chartier-Kastler E,
Bitker MO, Richard F, Camparo P, Capron F and Cussenot O:
Prognostic value of MET, RON and histoprognostic factors for
urothelial carcinoma in the upper urinary tract. J Urol.
179:868–872. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY,
Chang TY, Ho CL, Tzai TS and Chow NH: Coexpression of RON and MET
is a prognostic indicator for patients with transitional-cell
carcinoma of the bladder. Br J Cancer. 92:1906–1914. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Q, Seol DW, Carr B and Zarnegar R:
Co-expression and regulation of Met and Ron proto-oncogenes in
human hepatocellular carcinoma tissues and cell lines. Hepatology.
26:59–66. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee WY, Chen HH, Chow NH, Su WC, Lin PW
and Guo HR: Prognostic significance of co-expression of RON and MET
receptors in node-negative breast cancer patients. Clin Cancer Res.
11:2222–2228. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee CT, Chow NH, Su PF, Lin SC, Lin PC and
Lee JC: The prognostic significance of RON and MET receptor
coexpression in patients with colorectal cancer. Dis Colon Rectum.
51:1268–1274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maggiora P, Lorenzato A, Fracchioli S,
Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio
PM and Flavia Di Renzo M: The RON and MET oncogenes are
co-expressed in human ovarian carcinomas and cooperate in
activating invasiveness. Exp Cell Res. 288:382–389. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Watanabe H, Yokoyama Y, Kokuryo T, Ebata
T, Igami T, Sugawara G, Mizuno T, Shimoyama Y and Nagino M:
Prognostic Value of hepatocyte growth factor receptor expression in
patients with perihilar cholangiocarcinoma. Ann Surg Oncol.
22:2235–2242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeng JY, Sharma S, Zhou YQ, Yao HP, Hu X,
Zhang R and Wang MH: Synergistic activities of MET/RON inhibitor
BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived
from pancreatic cancer and cancer stem cells. Mol Cancer Ther.
13:37–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Choueiri TK, Vaishampayan U, Rosenberg JE,
Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN,
Adams LM, et al: Phase II and biomarker study of the dual
MET/VEGFR2 inhibitor foretinib in patients with papillary renal
cell carcinoma. J Clin Oncol. 31:181–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shapiro GI, McCallum S, Adams LM, Sherman
L, Weller S, Swann S, Keer H, Miles D, Müller T, Lorusso P, et al:
A phase 1 dose-escalation study of the safety and pharmacokinetics
of once-daily oral foretinib, a multi-kinase inhibitor, in patients
with solid tumors. Invest New Drugs. 31:742–750. 2013. View Article : Google Scholar : PubMed/NCBI
|
